Search
Event
Leukemia & Lymphoma Society - Light The Night Walk
… Walk 2022-10-07 Join Team Roswell and team captain Dr. Matthew Cortese to support the Leukemia & Lymphoma Society as … Join Team Roswell and team captain Dr. Matthew Cortese to support the Leukemia & Lymphoma Society as …
Page with Layout
Meet the Hernandez-Ilizaliturri Lab Team
… J. Hernandez-Ilizaliturri, MD Hematologic Oncology Matthew Cortese, MD, MPH Medical Oncology and Hematology …
OncLive State of the Science Summit | Hematologic Malignancies
… Griffiths, MD Roswell Park Comprehensive Cancer Center Matthew Cortese, MD, MPH Roswell Park Comprehensive Cancer … 1027 ) 8:15 p.m. - Bispecific Antibodies in R/R DLBCL Matthew Cortese, MD, MPH 8:30 p.m. - Exploring Hodgkin's …
Chronic Lymphocytic Leukemia Care Team
… as stem cell or bone marrow transplants. Bio Reference Matthew Cortese, MD, MPH Medical Oncology and Hematology …
Department of Cancer Genetics & Genomics Faculty
… of Cancer Genetics and Genomics View the Bakin Lab Matthew Cortese, MD, MPH Assistant Professor of Oncology …
News
Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
… Response to CAR T for Chronic Lymphocytic Leukemia Dr. Matthew Cortese highlights new findings in talk at American Society … (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH , Assistant Professor of Oncology in … (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH , Assistant Professor of Oncology in …
Lymphoma Care Team
… as stem cell or bone marrow transplants. Bio Reference Matthew Cortese, MD, MPH Medical Oncology and Hematology …
News
Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma
… Oral abstracts at ASH 2024 highlight studies led by Drs. Matthew Cortese and Kara Kelly Study clarifies impact of CAR T-cell … That’s the conclusion of a retrospective study led by Matthew Cortese, MD, MPH , Assistant Professor of Oncology in … That’s the conclusion of a retrospective study led by Matthew Cortese, MD, MPH , Assistant Professor of Oncology in …
Clinical Trial
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
… BGB-16673 in Patients With B-Cell Malignancies I Cortese, Matthew J Study consists of two main parts to explore …